Markers of Bone Destruction and Oxidative Stress in Peri-implantitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorSaglik Bilimleri Universitesi
About this trial
The aim of this study is to evaluate and compare the levels of bone resorption (RANKL, OPG) and oxidative stress (Nitrotyrosine, NQO1) markers, along with pro-inflammatory cytokines (IL-1β), in the saliva and peri-implant sulcular fluid (PISF) of patients with peri-implantitis, periodontitis, and healthy individuals. The study seeks to determine the diagnostic value of these biomarkers in the early detection and progression of peri-implant diseases.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients who apply to the University of Health Sciences, Gulhane Faculty of Dentistry, Department of Periodontology, and meet the specific clinical and radiographic criteria for peri-implantitis, periodontitis, or health.
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
80 Participants
are grouped into 4 trial groupsGroup A: Peri-implantitis Group
Group B: Periodontitis Group
Group C: Peri-implant Health Group
Group D: Periodontal Health Group
Trial outcomes
Primary outcomes
1
Salivary and Peri-implant Sulcular Fluid (PISF) IL-1β Levels.
The concentration of Interleukin-1 beta (IL-1β), a pro-inflammatory cytokine, will be measured in picograms per milliliter (pg/mL) using ELISA kits to evaluate the severity of inflammation and bone destruction.
Time frame
At the baseline clinical examination (Day 0).Secondary outcomes
1
Salivary and Peri-implant Sulcular Fluid (PISF) Nitrotyrosine Levels
Concentration of Nitrotyrosine will be measured in saliva and PISF samples using ELISA kits. Nitrotyrosine serves as a biochemical marker of nitrosative stress to evaluate oxidative damage.
Time frame
Baseline (at the time of clinical examination)2
Salivary and Peri-implant Sulcular Fluid (PISF) NQO1 Levels
NAD(P)H: Quinone Oxidoreductase 1 (NQO1) levels will be measured using ELISA kits to assess the local and systemic antioxidant defense response.
Time frame
Baseline (at the time of clinical examination)3
Salivary and Peri-implant Sulcular Fluid (PISF) RANKL Levels
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) levels will be measured to evaluate osteoclast activation and bone destruction potential.
Time frame
Baseline (at the time of clinical examination)4
Salivary and Peri-implant Sulcular Fluid (PISF) OPG Levels
Osteoprotegerin (OPG) levels will be measured. OPG acts as a decoy receptor for RANKL, and its level indicates the body's attempt to inhibit bone resorption.
Time frame
Baseline (at the time of clinical examination)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov